2008
The Association of Hashimoto Disease and Congo Red Negative Amyloidosis
Chaiban JT, Kalache SM, Salti I, Abu Alfa A, Shabb N. The Association of Hashimoto Disease and Congo Red Negative Amyloidosis. The American Journal Of The Medical Sciences 2008, 336: 293-296. PMID: 18794630, DOI: 10.1097/maj.0b013e31815b9d51.Peer-Reviewed Original ResearchConceptsCongo red stainHashimoto's thyroiditisPrimary amyloidosisMultiple organ involvementRed stainMonoclonal immunoglobulin light chainsOrgan involvementRenal failureHeart failureHashimoto's diseaseAmyloid depositionEnlarged tongueRare caseImmunoglobulin light chainsSystemic amyloidosisExtracellular depositionImmunofixation studiesAmyloidosisUltrastructural featuresThyroiditisPatientsLight chainStainEarly stagesBiopsy
2000
Ace inhibitors do not induce recombinant human erythropoietin resistance in hemodialysis patients
Abu-Alfa A, Cruz D, Perazella M, Mahnensmith R, Simon D, Bia M. Ace inhibitors do not induce recombinant human erythropoietin resistance in hemodialysis patients. American Journal Of Kidney Diseases 2000, 35: 1076-1082. PMID: 10845820, DOI: 10.1016/s0272-6386(00)70043-6.Peer-Reviewed Original ResearchMeSH KeywordsAnemiaAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsBlood PressureBlood TransfusionCross-Over StudiesDiabetes ComplicationsDrug ResistanceEpoetin AlfaErythropoietinFemaleFollow-Up StudiesHematinicsHematocritHospitalizationHumansInfectionsKidney Failure, ChronicLisinoprilMaleMiddle AgedProspective StudiesRecombinant ProteinsRenal DialysisTime FactorsConceptsACE inhibitor therapyACE inhibitorsHemodialysis patientsRHuEPO resistanceInhibitor therapyRecombinant human erythropoietin resistanceRecombinant human erythropoietin (rHuEPO) requirementsBlood pressure controlChronic renal failureDuration of infectionRHuEPO doseTransfusion requirementsErythropoietin resistanceRenal failureDialysis patientsHospitalization daysLaboratory parametersRHuEPO dosesAntihypertensive agentsCrossover studyErythropoietin requirementsInclusion criteriaPatientsAverage ageEnzyme inhibitors
1996
Angiotensin-converting enzyme inhibitor therapy in chronic hemodialysis patients: Any evidence of erythropoietin resistance?
Cruz D, Perazella M, Abu-Alfa A, Mahnensmith R. Angiotensin-converting enzyme inhibitor therapy in chronic hemodialysis patients: Any evidence of erythropoietin resistance? American Journal Of Kidney Diseases 1996, 28: 535-540. PMID: 8840943, DOI: 10.1016/s0272-6386(96)90464-3.Peer-Reviewed Original ResearchConceptsChronic hemodialysis patientsEnzyme inhibitor therapyACE inhibitorsHemodialysis patientsInhibitor therapySevere anemiaGroup 2Group 1End-stage renal diseaseExacerbation of anemiaSuppression of angiotensinChronic renal failureCongestive heart failureTherapy of anemiaBone marrow responseSignificant differencesRed blood cell productionRecombinant human EpoRHuEPO responseChronic hemodialysisErythropoietin resistanceRenal transplantationBaseline characteristicsHospital daysRenal failure
1992
Uremic Pancreopathy: Impaired Secretory Function In Vitro
Abu-Alfa A, Mujais S. Uremic Pancreopathy: Impaired Secretory Function In Vitro. American Journal Of Kidney Diseases 1992, 20: 585-588. PMID: 1462987, DOI: 10.1016/s0272-6386(12)70223-8.Peer-Reviewed Original ResearchConceptsSecretory responsePair-fed shamResult of derangementsExocrine pancreatic functionLeucine incorporationRenal failurePancreatic functionProtein synthesisProtein secretionSecretory functionPancreatic aciniExocrine pancreasAbnormalitiesCarbacholSecretionPresent studyAciniDNA contentUremiaDerangementShamPancreasRats